2014

Taiwan Pharmaceutical Market Outlook 2013

NEW YORK, June 13, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Taiwan Pharmaceutical Market Outlook 2013


http://www.reportlinker.com/p01351965/Taiwan-Pharmaceutical-Market-Outlook-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Managed_care


Taiwan Pharmaceutical Market Outlook 2013

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Taiwan Pharmaceutical Market Outlook 2013". The report focuses on the Taiwanese pharmaceutical market, providing market analysis and a forecast to 2018. It provides details on the various market drivers and healthcare trends that influence growth in Taiwan's pharmaceutical industry. The report also profiles major biopharmaceutical companies in the country, both domestic and overseas players.

Taiwan's pharmaceutical market was worth $4.4 billion in 2012, having grown at a CAGR of 2.9%, and is estimated to reach $5.5 billion by 2018, growing at a CAGR of 3.9%. Although the size of the market is small compared with other growing markets in Asia, it is expected to provide a market entry point for companies wishing to launch their products in other larger markets.

Scope

- Political, economic and investment environment in Taiwan
- Healthcare and insurance system, healthcare infrastructure and key policy initiatives
- Market size estimation, analysis of key therapeutic areas and emerging areas
- Profiles of major biopharmaceutical companies in Taiwan, such as Pfizer, Sanofi Aventis, GSK and Novartis, and key domestic players such as China Chemical & Pharmaceutical Company, Standard Chemicals & Pharmaceuticals and Yung Shin Pharmaceutical.
- Key drivers and barriers that have had a significant impact on the market

Reasons to buy

- Identify potential therapeutic areas in Taiwan that are poised for growth
- Build effective market entry and expansion strategies for introducing products in Taiwan
- Develop key strategic initiatives by studying top competitors' key strategies
- Reinforce R&D pipelines by identifying new target mechanisms that can produce first-in-class molecules with more efficacy and better safety

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 9
2 Taiwan Pharmaceutical Market Outlook 2013 – Introduction 11
2.1 Taiwan Pharmaceutical Market 11
3 Taiwan Pharmaceutical Market Outlook 2013 – Investment Environment 12
3.1 Government and Political Environment 12
3.2 Taiwan Economic Outlook 12
3.3 Foreign Trade and Investment 14
3.4 Investment Incentives – Government Boosting the Biotech Sector 16
3.4.1 Act for the Development of Biotech and New Pharmaceuticals Industry (2007) 16
3.4.2 Diamond Action Plan for Biotechnology Takeoff (2009) 16
3.5 International Appraisal and Membership 17
3.5.1 Patent Prosecution Highway Pilot program 17
3.5.2 Pharmaceutical Inspection Convention and Inspection Cooperation Scheme 17
4 Taiwan Pharmaceutical Market Outlook 2013 – Healthcare System 18
4.1 Healthcare System 18
4.1.1 Department of Health 18
4.1.2 Bureau of National Health Insurance 19
4.1.3 Health Insurance Coverage 20
4.1.4 Health Insurance System Challenges 22
4.1.5 Health Policy Initiatives 23
4.2 Healthcare Expenditure 24
4.2.1 Healthcare Spending 24
4.2.2 Healthcare Expenditure by Type of Service 27
4.2.3 Healthcare Expenditure on Pharmaceutical Products 28
4.2.4 Public Health Expenditure 30
4.3 Healthcare Infrastructure 32
4.3.1 Healthcare Facilities 32
4.3.2 Healthcare Coverage 33
4.3.3 Healthcare Personnel 35
4.4 Population Health 39
4.4.1 Demographics 39
4.4.2 Life Expectancy 41
4.4.3 Mortality 43
5 Taiwan Pharmaceutical Market Outlook 2013 – Regulatory Landscape 45
5.1 Drug Pricing and Reimbursement 45
5.1.1 Drug Reimbursement 45
5.1.2 Pricing Policies 45
5.1.3 Pricing Trends 47
5.1.4 Challenges in the Reimbursement Process 48
5.1.5 Drug Expenditure Target 49
5.2 Policy and Regulatory Environment in Taiwan 49
5.2.1 New Drug Approval 49
5.2.2 Intellectual Property Rights 50
6 Taiwan Pharmaceutical Market Outlook 2013 – Market Overview 52
6.1 Pharmaceutical Market Overview 52
6.2 Pharmaceutical Market Size 53
6.3 Market Segments 54
6.4 Key Therapeutic Areas 58
6.4.1 Respiratory Diseases 61
6.4.2 Digestive Diseases 64
6.4.3 Genitourinary Diseases 67
6.4.4 Circulatory Diseases 69
6.4.5 Malignant Neoplasms 72
6.5 Emerging Areas 77
6.5.1 Orphan Drugs 77
6.6 Drug Distribution and Pharmaceutical Supply Chain 78
6.7 Spending in Pharmaceutical R&D 79
7 Taiwan Pharmaceutical Market Outlook 2013 – Competitive Landscape 80
7.1 Key Foreign Entities 80
7.1.1 Pfizer 80
7.1.2 Sanofi 85
7.1.3 Novartis 89
7.1.4 GlaxoSmithKline 94
7.2 Key Domestic Players 100
7.2.1 The China Chemical & Pharmaceutical Company 100
7.2.2 Standard Chemicals & Pharmaceuticals Co. Ltd. 103
7.2.3 Yung Shin Pharmaceutical. Ind. Co. Ltd. 106
7.2.4 ScinoPharm Taiwan 109
7.2.5 TTY Biopharm Company Limited 114
8 Taiwan Pharmaceutical Market Outlook 2013 – Market Dynamics 117
8.1 Industry Drivers and Opportunities 117
8.2 Barriers to Entry 117
8.3 Recent Industry Activity and Consolidation 118
9 Taiwan Pharmaceutical Market Outlook 2013 – the Way Forward 119
9.1 Key Insights 119
9.2 Market Opportunities 119
9.3 Future Market Outlook 120
10 Taiwan Pharmaceutical Market Outlook 2013 – Appendix 121
10.1 Market Definitions 121
10.2 Abbreviations 121
10.3 Bibliography 123
10.4 Research Methodology 126
10.4.1 Coverage 127
10.4.2 Secondary Research 127
10.4.3 Primary Research 127
10.4.4 Expert Panel Validation 128
10.5 Contact Us 128
10.6 Disclaimer 128

1.1 List of Tables

Table 1: Pharmaceutical Market, Taiwan, Economic Indicators (%), 2008 – 2012 October 13
Table 2: Pharmaceutical Market, Taiwan, Trade with Top 10 Countries ($bn), 2012 15
Table 3: Pharmaceutical Market, Taiwan, Persons Under Social Insurance, ('000, %), 2002 – 2012 20
Table 4: Pharmaceutical Market, Taiwan, BNHI Revenues and Costs ($bn), 2002 – 2012 22
Table 5: Pharmaceutical Market, Taiwan, National Health Expenditure (TWDbn, $bn), 2003 – 2012 24
Table 6: Pharmaceutical Market, Taiwan, Healthcare Expenditure as Percentage of GDP (%), 2006 – 2012 25
Table 7: Pharmaceutical Market, Taiwan, OECD Countries, Healthcare Expenditure as Percentage of GDP (%), 2006 – 2012 26
Table 8: Pharmaceutical Market, Taiwan, NHI Healthcare Expenditure by Type of Service ($bn), 2006 – 2011 27
Table 9: Pharmaceutical Market, Taiwan, Drug Expenditure ($bn), 2006 – 2012 28
Table 10: Pharmaceutical Market, Taiwan, Pharmaceutical Product Expenditure (%), 2006 – 2012 28
Table 11: Pharmaceutical Market, Taiwan, OECD Countries, Drug Expenditure (%), 2006 – 2012 29
Table 12: Pharmaceutical Market, Taiwan, OECD Countries, Out-of-Pocket Expenditure as Percentage of Healthcare Expenditure (%), 2006 – 2012 30
Table 13: Pharmaceutical Market, Taiwan, Public-Private Share of Healthcare Expenditure (%), 2006 – 2012 31
Table 14: Pharmaceutical Market, Taiwan, OECD Countries, Public Spending as Percentage of Total Health Expenditure (%), 2006 – 2012 31
Table 15: Pharmaceutical Market, Taiwan, NHI-contracted Healthcare Institutions by Type, 2006 – 2012 32
Table 16: Pharmaceutical Market, Taiwan, Hospital Beds per 1,000 Population, 2006 – 2012 33
Table 17: Pharmaceutical Market, Taiwan, OECD Countries, Hospital Beds per 1,000 Population, 2006 – 2012 34
Table 18: Pharmaceutical Market, Taiwan, Physicians per 1,000 Population, 2006 – 2012 35
Table 19: Pharmaceutical Market, Taiwan, OECD Countries, Physicians per 1,000 Population, 2006 – 2012 36
Table 20: Pharmaceutical Market, Taiwan, Nurses per 1,000 Population, 2006 – 2012 37
Table 21: Pharmaceutical Market, Taiwan, Healthcare Professionals by Type ('000), 2006 – 2012 37
Table 22: Pharmaceutical Market, Taiwan, Pharmacists per 1,000 Population, 2006 – 2012 38
Table 23: Pharmaceutical Market, Taiwan, Population by Gender ('000), 2006 – 2012 39
Table 24: Pharmaceutical Market, Taiwan, Population by Age (%), 2002 – 2012 40
Table 25: Pharmaceutical Market, Taiwan, Life Expectancy at Birth by Gender and Age (Years), 2002 – 2011 41
Table 26: Pharmaceutical Market, Taiwan, Life Expectancy at Birth (Years), 2004 – 2011 42
Table 27: Pharmaceutical Market, OECD Countries, Life Expectancy at Birth (Years), 2004 – 2011 42
Table 28: Pharmaceutical Market, Taiwan, Mortality Rate (per 1,000 population), 2002 – 2011 43
Table 29: Pharmaceutical Market, Taiwan, Cause of Deaths by Type of Disease ('000), 2002 – 2011 44
Table 30: Pharmaceutical Market, Taiwan, Price Trend in Medicines and Medical Care (%), 2006 – 2012 47
Table 31: Pharmaceutical Market, Taiwan Intellectual Property Rights, 2012 50
Table 32: Pharmaceutical Market, Taiwan, Revenue ($bn, TWDbn), 2006 – 2012 53
Table 33: Pharmaceutical Market, Taiwan, Revenue Forecast ($bn, TWDbn), 2012 – 2018 53
Table 34: Pharmaceutical Market, Taiwan, Generics, Revenue ($bn), 2006 – 2012 54
Table 35: Pharmaceutical Market, Taiwan, Generics, Revenue Forecast ($bn), 2012 – 2018 55
Table 36: Pharmaceutical Market, Taiwan, Over-the-Counter, Revenue ($m), 2006 – 2012 57
Table 37: Pharmaceutical Market, Taiwan, National Health Expenditure by Therapeutic Area ($bn), 2006 – 2012 59
Table 38: Pharmaceutical Market, Taiwan, National Health Expenditure by Therapeutic Area and Age ($m), 2012 60
Table 39: Pharmaceutical Market, Taiwan, National Health Expenditure on Respiratory Diseases ($m), 2006 – 2012 62
Table 40: Pharmaceutical Market, Taiwan, National Health Expenditure on Respiratory Diseases by Year and Age ($m), 2006 – 2012 63
Table 41: Pharmaceutical Market, Taiwan, National Health Expenditure on Digestive Diseases by Year ($m), 2006 – 2012 65
Table 42: Pharmaceutical Market, Taiwan, National Health Expenditure on Digestive Diseases by Year and Age ($m), 2006 – 2012 66
Table 43: Pharmaceutical Market, Taiwan, National Health Expenditure on Genitourinary Diseases ($m), 2006 – 2012 67
Table 44: Pharmaceutical Market, Taiwan, National Health Expenditure on Genitourinary Diseases by Year and Age ($m), 2006 – 2012 68
Table 45: Pharmaceutical Market, Taiwan, National Health Expenditure on Circulatory Diseases by Year ($m), 2006 – 2012 70
Table 46: Pharmaceutical Market, Taiwan, National Health Expenditure on Circulatory Diseases by Year and Age ($m), 2006 – 2012 71
Table 47: Pharmaceutical Market, Taiwan, National Health Expenditure on Malignant Neoplasms by Year ($m), 2006 – 2012 73
Table 48: Pharmaceutical Market, Taiwan, National Health Expenditure on Malignant Neoplasms by Year and Age ($m), 2006 – 2012 74
Table 49: Pharmaceutical Market, Taiwan, Top Five Leading Causes of Cancer, Males, Incidence Rate, 2006 and 2008 75
Table 50: Pharmaceutical Market, Taiwan, Top Five Leading Causes of Cancer, Females, Incidence Rate, 2006 and 2008 75
Table 51: Pharmaceutical Market, Taiwan, Government Interventions for Cancer Prevention and Control, 1995 – 2008 76
Table 52: Pharmaceutical Market, Taiwan, Market Comparison between the US and Taiwan, 2012 78
Table 53: Pharmaceutical Market, Taiwan, R&D Expenditure ($m), 2005 – 2011 79
Table 54: Pharmaceutical Market, Global, Pfizer, Revenue ($bn), 2007 – 2012 81
Table 55: Pharmaceutical Market, Taiwan, Pfizer, Major Products by Type, 2012 82
Table 56: Pharmaceutical Market, Global, Pfizer, Pipeline Products by Therapy Area, 2012 83
Table 57: Pharmaceutical Market, Global, Pfizer, Pipeline Products by Development Phase, 2012 84
Table 58: Pharmaceutical Market, Global, Sanofi, Revenue ($bn), 2007 – 2012 86
Table 59: Pharmaceutical Market, Taiwan, Sanofi, Major Products by Therapy Area, 2012 87
Table 60: Pharmaceutical Market, Global, Sanofi, Number of Pipeline Products by Therapy Area, 2012 88
Table 61: Pharmaceutical Market, Global, Sanofi, Number of Pipeline Products by Development Phase, 2012 88
Table 62: Pharmaceutical Market, Global, Novartis, Financial Performance ($bn), 2007 – 2012 90
Table 63: Pharmaceutical Market, Global, Novartis, Major Products by Therapy Area, 2012 91
Table 64: Pharmaceutical Market, Global, Novartis, Number of Pipeline Products by Therapy Area, 2012 92
Table 65: Pharmaceutical Market, Global, Novartis, Number of Pipeline Products by Developmental Phase, 2012 93
Table 66: Pharmaceutical Market, Global, GlaxoSmithKline, Financial Performance ($m), 2007 – 2012 96
Table 67: Pharmaceutical Market, Global, GlaxoSmithKline, Major Products, Therapy Areas, Brands, 2012 97
Table 68: Pharmaceutical Market, Global, GlaxoSmithKline, Number of Pipeline Products by Therapy Area, 2012 98
Table 69: Pharmaceutical Market, Global, GlaxoSmithKline, Number of Pipeline Products by Development Phase, 2012 99
Table 70: Pharmaceutical Market, Taiwan, China Chemical & Pharmaceutical, Revenue ($m), 2007 – 2012 101
Table 71: Pharmaceutical Market, Taiwan, China Chemical & Pharmaceutical, Major Products by Therapy Area, 2012 102
Table 72: Pharmaceutical Market, Taiwan, Standard Chemical & Pharmaceutical, Revenue ($m) 2007 – 2012 104
Table 73: Pharmaceutical Market, Taiwan, Standard Chemical & Pharmaceuticals, Major Products, 2012 105
Table 74: Pharmaceutical Market, Taiwan, Standard Chemical & Pharmaceuticals, Product Patents, 2001 – 2010 105
Table 75: Pharmaceutical Market, Taiwan, Standard Chemical & Pharmaceuticals, Product Awards, 2001 – 2010 106
Table 76: Pharmaceutical Market, Taiwan, Yung shin Pharmaceutical, Revenue ($m), 2007 – 2012 107
Table 77: Pharmaceutical Market, Taiwan, Yung Shin Pharmaceutical, Product Lines, 2012 108
Table 78: Pharmaceutical Market, Taiwan, Yung Shin Pharmaceuticals, Latest Products by Disease Type, 2012 108
Table 79: Pharmaceutical Market, Taiwan, Yung Shin Pharmaceuticals, Major Products, Active Pharmaceutical Ingredients, 2012 108
Table 80: Pharmaceutical Market, Taiwan, ScinoPharm Taiwan, Revenue ($m), 2007 – 2012 110
Table 81: Pharmaceutical Market, Taiwan, ScinoPharm Taiwan, Sales by Region (%), 2011 111
Table 82: Pharmaceutical Market, Taiwan, ScinoPharm, Major Products by Therapeutic Area, 2012 112
Table 83: Pharmaceutical Market, Taiwan, TTY Biopharm, Revenue ($m), 2007 – 2012 114
Table 84: Pharmaceutical Market, Taiwan, TTY Biopharm, Major Products by Therapy Area, 2012 115
Table 85: Pharmaceutical Market, Taiwan, TTY Biopharm, Pipeline Products by Therapy Area and Development Phase, 2012 116

1.2 List of Figures

Figure 1: Pharmaceutical Market, Taiwan, Economic Indicators (%), 2008 – 2012 October 12
Figure 2: Pharmaceutical Market, Taiwan, Trade with Top 10 Countries ($bn), 2012 14
Figure 3: Pharmaceutical Market, Taiwan, BNHI's Function in Taiwan's Healthcare System, 2012 19
Figure 4: Pharmaceutical Market, Taiwan, BNHI Revenues and Cost ($bn), 2002 – 2012 22
Figure 5: Pharmaceutical Market, Taiwan, Healthcare Expenditure as Percentage of GDP (%), 2006 – 2012 25
Figure 6: Pharmaceutical Market, Taiwan, OECD Countries, Healthcare Expenditure as Percentage of GDP (%), 2006 – 2012 26
Figure 7: Pharmaceutical Market, Taiwan, NHI Healthcare Expenditure of Type of Service (%), 2011 27
Figure 8: Pharmaceutical Market, Taiwan, Drug Expenditure ($bn), 2006 – 2012 28
Figure 9: Pharmaceutical Market, Taiwan, OECD Countries, Drug Expenditure (%), 2006 – 2012 29
Figure 10: Pharmaceutical Market, Taiwan, Out-of-Pocket Expenditure as Percentage of Healthcare Expenditure (%), 2006 – 2012 30
Figure 11: Pharmaceutical Market, Taiwan, NHI-contracted Healthcare Institutions by Type, 2006 – 2012 32
Figure 12: Pharmaceutical Market, Taiwan, OECD Countries, Hospital Beds per 1,000 Population, 2006 – 2012 34
Figure 13: Pharmaceutical Market, Taiwan, Physicians per 1,000 Population, 2006 – 2012 35
Figure 14: Pharmaceutical Market, Taiwan, OECD Countries, Physicians per 1,000 Population, 2006 – 2012 36
Figure 15: Pharmaceutical Market, Taiwan, Nurses per 1,000 Population, 2006 – 2012 37
Figure 16: Pharmaceutical Market, Taiwan, Pharmacists per 1,000 Population, 2006 – 2012 38
Figure 17: Pharmaceutical Market, Taiwan, Population by Gender, ('000), 2006 – 2012 39
Figure 18: Pharmaceutical Market, Taiwan, Population by Age (%), 2002 – 2012 40
Figure 19: Pharmaceutical Market, Taiwan, Life Expectancy at Birth by Gender and Age (Years), 2002 – 2011 41
Figure 20: Pharmaceutical Market, Taiwan, OECD Countries, Life Expectancy at Birth (Years), 2004 – 2011 42
Figure 21: Pharmaceutical Market, Taiwan, Cause of Death by Type of Disease ('000, %), 2002 – 2011 43
Figure 22: Pharmaceutical Market, Taiwan, Pricing and Reimbursement by Drug Type, 2012 46
Figure 23: Pharmaceutical Market, Taiwan, Price Trend in Medicines and Medical Care (%), 2006 – 2012 47
Figure 24: Pharmaceutical Market, Taiwan, Revenue Forecast ($bn), 2006 – 2018 53
Figure 25: Pharmaceutical Market, Taiwan, Generics, Revenues ($bn), 2006 – 2012 54
Figure 26: Pharmaceutical Market, Taiwan, Generics, Revenue Forecast ($bn), 2012 – 2018 55
Figure 27: Pharmaceutical Market, Taiwan, Over-the-Counter, Revenue ($m), 2006 – 2012 57
Figure 28: Pharmaceutical Market, Taiwan, National Health Expenditure by Therapeutic Area (%), 2012 58
Figure 29: Pharmaceutical Market, Taiwan, National Health Expenditure by Therapeutic Area ($bn), 2006 – 2012 59
Figure 30: Pharmaceutical Market, Taiwan, National Health Expenditure by Therapeutic Area and Age ($m), 2012 60
Figure 31: Pharmaceutical Market, Taiwan, National Health Expenditure on Respiratory Diseases ($m), 2006 – 2012 61
Figure 32: Pharmaceutical Market, Taiwan, Drug Expenditure on Respiratory Diseases ($m), 2006 – 2012 62
Figure 33: Pharmaceutical Market, Taiwan, National Health Expenditure on Respiratory Diseases by Year and Age ($m), 2006 – 2012 63
Figure 34: Pharmaceutical Market, Taiwan, National Health Expenditure on Digestive Diseases ($m), 2006 – 2012 64
Figure 35: Pharmaceutical Market, Taiwan, Drug Expenditure on Digestive Diseases ($m), 2006 – 2012 65
Figure 36: Pharmaceutical Market, Taiwan, National Health Expenditure on Digestive Diseases by Year and Age ($m), 2006 – 2012 66
Figure 37: Pharmaceutical Market, Taiwan, National Health Expenditure on Genitourinary Diseases ($m), 2006 – 2012 67
Figure 38: Pharmaceutical Market, Taiwan, NHE on Genitourinary Diseases, by Year and Age ($m), 2006 – 2012 68
Figure 39: Pharmaceutical Market, Taiwan, National Health Expenditure on Circulatory Diseases ($m), 2006 – 2012 69
Figure 40: Pharmaceutical Market, Taiwan, Drug Expenditure on Circulatory Diseases ($m), 2006 – 2012 70
Figure 41: Pharmaceutical Market, Taiwan, National Health Expenditure on Circulatory Diseases by Year and Age ($m), 2006 – 2012 71
Figure 42: Pharmaceutical Market, Taiwan, National Health Expenditure on Malignant Neoplasms ($m), 2006 – 2012 72
Figure 43: Pharmaceutical Market, Taiwan, Drug Expenditure on Malignant Neoplasms ($m), 2006 – 2012 73
Figure 44: Pharmaceutical Market, Taiwan, National Health Expenditure on Malignant Neoplasms by Year and Age ($m), 2006 – 2012 74
Figure 45: Pharmaceutical Market, Taiwan, R&D Expenditure ($m), 2005 – 2011 79
Figure 46: Pharmaceutical Market, Global, Pfizer, Revenue ($bn), 2007 – 2012 81
Figure 47: Pharmaceutical Market, Global, Pfizer, Pipeline Products by Therapy Area, 2012 83
Figure 48: Pharmaceutical Market, Global, Pfizer, Pipeline Products by Development Phase, 2012 84
Figure 49: Pharmaceutical Market, Global, Sanofi, Revenue ($bn), 2007 – 2012 86
Figure 50: Pharmaceutical Market, Global, Novartis, Revenue ($bn), 2007 – 2012 90
Figure 51: Pharmaceutical Market, Global, GlaxoSmithKline, Revenue ($bn), 2007 – 2012 96
Figure 52: Pharmaceutical Market, Taiwan, China Chemical & Pharmaceutical, Revenue ($m), 2007 – 2012 101
Figure 53: Pharmaceutical Market, Taiwan, Standard Chemical & Pharmaceutical, Revenue ($m), 2007 – 2012 104
Figure 54: Pharmaceutical Market, Taiwan, Yung shin Pharmaceutical, Revenue ($m), 2007 – 2012 107
Figure 55: Pharmaceutical Market, Taiwan, ScinoPharm Taiwan, Revenue ($m), 2007 – 2012 110
Figure 56: Pharmaceutical Market, Taiwan, ScinoPharm Taiwan, Sales by Region (%), 2011 111
Figure 57: Pharmaceutical Market, Taiwan, TTY Biopharm, Revenue ($m), 2007 – 2012 114

Companies Mentioned
Pfizer
Sanofi
Novartis
GlaxoSmithKline
The China Chemical & Pharmaceutical Company
Standard Chemicals & Pharmaceuticals Co. Ltd.
Yung Shin Pharmaceutical. Ind. Co. Ltd.
ScinoPharm Taiwan
TTY Biopharm Company Limited

To order this report:
Managed_care Industry:
Taiwan Pharmaceutical Market Outlook 2013

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.